NVS vs XFOR
NVS: Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience. XFOR: A biopharmaceutical company developing mavorixafor, an oral CXCR4 antagonist, to treat rare hematology conditions like chronic neutropenia and WHIM syndrome.
Side-by-side fundamentals
| Metric | NVS | XFOR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $143.11 | $2.79 | |
| Market cap | $227.4B | $277M | |
| P/E as of 2026-09-03 | 21.95 | n/a | |
| Net margin FY2025, SEC XBRL | n/a | -225.6% | |
| Operating margin FY2025, SEC XBRL | n/a | -247.4% | |
| ROE FY2025, SEC XBRL | +30.0% | -42.5% | NVS higher |
| ROA FY2025, SEC XBRL | +12.6% | -27.3% | NVS higher |
| Debt / equity as of 2026-09-03 | 1.18 | 0.45 | XFOR lower |
| Revenue growth (YoY) as of 2026-09-03 | +3.3% | -71.3% | NVS higher |
| Dividend yield as of 2026-09-03 | +3.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.23 | 1.29 | |
| 1-year return as of 2026-10-08 close | +8.2% | -16.0% | NVS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.